Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry

Volumn 23, Issue 13, 2015, Pages 3221-3227

  Li, Si Ning ^a   Xu, Yun Yun ^a   Gao, Jia Yu ^a   Yin, Hong Ran ^a   Zhang, Shi Lei ^a   Li, Huan Qiu ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

4 Anilinoquinazoline; EGFR TK inhibitors; Molecular docking; Rhodanine; Structure based design

Indexed keywords

1 [5 (2 BROMOBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 (2 CHLOROBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 (3 BROMOBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 (3 CHLOROBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 (4 CHLOROBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 [(1,10 BIPHENYL) 4 YLMETHYLENE] 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 [(5 BROMOTHIOPHEN 2 YL)METHYLENE] 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; 1 [5 [(6 BROMOPYRIDIN 2 YL)METHYLENE] 4 OXO 4,5 DIHYDROTHIAZOL 2 YL] N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL]PYRROLIDINE 2 CARBOXAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [4 OXO 5 (PYRIDIN 3 YLMETHYLENE) 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [4 OXO 5 (QUINOLIN 2 YLMETHYLENE) 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [4 OXO 5 (THIOPHEN 2 YLMETHYLENE) 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [5 (2 FLUOROBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [5 (2 METHOXYBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [5 (2 NITROBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [5 (4 METHOXYBENZYLIDENE) 4 OXO 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [5 [(2 CHLOROPYRIDIN 3 YL)METHYLENE] 4 OXO 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; N [4 [(3 CHLOROPHENYL)AMINO]QUINAZOLIN 6 YL] 1 [5 [(6 METHYLPYRIDIN 2 YL)METHYLENE] 4 OXO 4,5 DIHYDROTHIAZOL 2 YL]PYRROLIDINE 2 CARBOXAMIDE; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RHODANINE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HEPG2 CELL LINE; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHODANINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937414545     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2015.04.065     Document Type: Article

References (18)

1. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Science 235 1987 177
2. P.M. Traxler Expert Opin. Ther. Pat. 7 1997 571
3. D.W. Fry Annu. Rep. Med. Chem. 31 1996 151
4. D.W. Fry, A.J. Kraker, A. McMichael, L.A. Ambroso, J.M. Nelson, W.R. Leopold, R.W. Connors, and A.J. Bridges Science 265 1994 1093
5. W.H.J. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green Biochem. Pharmacol. 48 1994 659
6. A.J. Bridges, H. Zhou, D.R. Cody, G.W. Rewcastle, A. McMichael, H.D.H. Showalter, D.W. Fry, A.J. Kraker, and W.A. Denny J. Med. Chem. 39 1996 267
7. A.J. Bridges Curr. Med. Chem. 6 1999 825
8. D.H. Boschelli Drugs Future 24 1999 515
9. K. Iwata, P.E. Miller, E.G. Barbacci, L. Arnold, J. Doty, C.I. DiOrio, L.R. Pustilnik, M. Reynolds, A. Thelemann, D. Sloan, and J.D. Moyer Proc. Am. Assoc. Cancer Res. 38 1997 633 (Abstract 4248)
10. J.R. Woodburn, A.J. Barker, K.H. Gibson, S.E. Ashton, A.E. Wakeling, B.J. Curry, L. Scarlett, and L.R. Henthorn Proc. Am. Assoc. Cancer Res. 38 1997 633 (Abstract 4251)
11. Company Press Release, Feb 1, 2010: GSK's TYKERB receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer.
12. S.N. Li, and H.Q. Li Expert Opin. Ther. Pat. 24 2014 309
13. Y.Y. Xu, S.N. Li, G.J. Yu, Q.H. Hu, and H.Q. Li Bioorg. Med. Chem. 21 2013 6084
14. Y.Y. Xu, Y. Gao, H.K. Ma, G.Z. Ao, and H.Q. Li Bioorg. Med. Chem. 21 2013 388
15. H.Q. Li, D.D. Li, X. Lu, and H.L. Zhu Bioorg. Med. Chem. 20 2012 317
16. H.Q. Li, J. Yang, S.H. Ma, and C.H. Qiao Bioorg. Med. Chem. 20 2012 4194
17. Chai, C. C. L.; Bernardo, P. H., Xu, J. WO 2010/024783 A1. US Patent.
18. H.-R. Tsou, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F.E. Koehn, L.M. Greenberger, Y.-F. Wang, and A. Wissner J. Med. Chem. 44 2001 2719